Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02579928 · ClinicalTrials.gov registry record · Phase 4
Ketamine Infusion for Adolescent Depression and Anxiety
A Phase 4 study of Major Depressive Disorder and Anxiety Disorder, sponsored by Yale University.
- Completed
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
- 2
- Study locations
NCT02579928: Completed Phase 4 study of Major Depressive Disorder and Anxiety Disorder, sponsored by Yale University.
NCT02579928 is a Phase 4 study of Major Depressive Disorder and Anxiety Disorder that has completed, run by Yale University. The registered enrollment target is 17 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02579928, a Phase 4 study of Major Depressive Disorder and Anxiety Disorder, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the tolerability and short-term efficacy of a single ketamine infusion for the treatment of adolescents with 1) medication-refractory major depressive disorder (MDD) and/or 2) medication-refractory anxiety disorders (social anxiety disorder, panic disorder, generalized anxiety disorder and/or separation anxiety disorder).
Primary Outcome
Depressive symptoms (measured by Montgomery-Asberg Depression Rating Scale, revised (MADRS) score) on 1 day after infusion, for the cohort of subjects enrolled in the MDD arm of this trial. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. Usual cutoff points are: 0 to 6 - normal /symptom absent. 7 to 19 - mild depression. 20 to 34 - moderate depression. \>34 - severe depression.
Conditions Studied
Interventions
- DRUG Ketamine
- DRUG Midazolam
Study Locations (2)
Connecticut
- Hospital Research Unit at the Yale New Haven Hospital - New Haven
- Yale Child Study Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2015-10 |
| Est. Completion | 2019-09 |
| Phase | Phase 4 |
What the finished NCT02579928 record still lists
NCT02579928 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Ketamine is the first listed.
NCT02579928 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT02579928 about?
NCT02579928 is a clinical study titled "Ketamine Infusion for Adolescent Depression and Anxiety". The purpose of this study is to determine the tolerability and short-term efficacy of a single ketamine infusion for the treatment of adolescents with 1) medication-refractory major depressive disorder (MDD) and/or 2) medication-refractory anxiety disorders (social anxiety disorder, panic disorder, ...
What is the current status of trial NCT02579928?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2015-10. Estimated completion is 2019-09.
What conditions does trial NCT02579928 study?
This clinical trial studies the following conditions: Major Depressive Disorder, Anxiety Disorder.
What interventions are being tested in trial NCT02579928?
The interventions under investigation include: Ketamine (DRUG), Midazolam (DRUG).
Who is sponsoring clinical trial NCT02579928?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02579928 being conducted?
This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02579928's enrollment target sits among peer trials
17 254th of 282 higher than 27 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
RECRUITING · Phase 4
-
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
RECRUITING · Phase 4
-
Neural Circuit Effects of Ketamine in Depression
RECRUITING · Phase 4
-
Aβ Dynamics in LLMD
RECRUITING · Phase 4
-
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia